Abstract
Many risk factors lead to hypohepatia and hepatic failure, causing people suffering from end-stage liver disease. The conventional treatment for end-stage liver disease is not good enough. Orthotopic liver transplantation is effective. However, the high cost, lack of liver source, immune rejection and other factors limit the large-scale clinical application. Thus, cell therapy is a good option. Studies on common cell sources for the treatment of liver disease and the induction of hepatocytes by embryonic stem cells or pluripotent stem cells have made progress. With the development of stem cell technology, cell transplantation has become a new option, which brings hope to people with end-stage liver diseasetransplantation has become a new option. It brings hope to people with end-stage liver disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
